A multicentric open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, steady state, comparative bioavailability evaluation of Clozapine extended release capsule 200 mg once daily (test drug, Intas pharmaceuticals limited, India) with clozaril® 100 mg tablets twice daily (reference drug, Novartis pharmaceuticals corporation, USA) after multiple dose administration in adult schizophrenic patients under fasting conditions - NA

Trial Profile

A multicentric open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, steady state, comparative bioavailability evaluation of Clozapine extended release capsule 200 mg once daily (test drug, Intas pharmaceuticals limited, India) with clozaril® 100 mg tablets twice daily (reference drug, Novartis pharmaceuticals corporation, USA) after multiple dose administration in adult schizophrenic patients under fasting conditions - NA

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Clozapine (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Intas Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top